E Karlsson1, K Sandelin2, J Appelgren3, W Zhou4, K Jirström5, J Bergh6, F Wärnberg7. 1. Department of Oncology-Pathology, Radiumhemmet, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden; Department of Oncology, Central Hospital Karlstad, Karlstad, Sweden. Electronic address: Eva.Karlsson@ki.se. 2. Department of Surgery, Karolinska University Hospital, Stockholm, Sweden. 3. Department of Economics and Statistics, Karlstad University, Karlstad, Sweden. 4. Department of Surgery, Uppsala University, Uppsala, Sweden. 5. Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. 6. Department of Oncology-Pathology, Radiumhemmet, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden. 7. Department of Surgery, Uppsala University Hospital, Uppsala, Sweden.
Abstract
BACKGROUND: Emerging data propose biomarker alteration due to clonal selection between the primary invasive breast cancer and corresponding metastases. In addition, impact on survival has been demonstrated. The present study investigates the relationship between the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) between primary ductal carcinoma in situ (DCIS) and intra-individually matched ipsilateral event. MATERIALS AND METHODS: The cohort includes 1504 patients, diagnosed with a primary DCIS between 1986 and 2004. Of the 274 patients who developed a local relapse, 135 developed a new in situ carcinoma and 139 an invasive cancer up to 31st December 2011. ER and PR were identified by immunohistochemistry (IHC) and HER2 by silver-enhanced in situ hybridisation (SISH) as well as IHC. RESULTS: ER (n=112), PR (n=113) and HER2 (n=114) status from both the primary DCIS and the corresponding relapse were assessed and were demonstrated to be discordant in 15.1%, 29.2% and 10.5% respectively. The receptor conversion was both from negative to positive and from positive to negative with no general pattern being seen in spite of sub-dividing into in situ relapse and invasive relapse. However, primary DCIS was HER2 positive in 40.3% whereas in situ and invasive relapses were HER2 positive in 42.9% and 34.5% respectively. CONCLUSIONS: Receptor conversion for ER, PR and HER2 status occurred between primary DCIS and corresponding local relapse in 10-30%. This study could not confirm that HER2 overexpression in primary DCIS had any impact on tumour progression to invasive cancer which has been proposed.
BACKGROUND: Emerging data propose biomarker alteration due to clonal selection between the primary invasive breast cancer and corresponding metastases. In addition, impact on survival has been demonstrated. The present study investigates the relationship between the oestrogen receptor (ER), progesterone receptor (PR) and humanepidermal growth factor receptor 2 (HER2) between primary ductal carcinoma in situ (DCIS) and intra-individually matched ipsilateral event. MATERIALS AND METHODS: The cohort includes 1504 patients, diagnosed with a primary DCIS between 1986 and 2004. Of the 274 patients who developed a local relapse, 135 developed a new in situ carcinoma and 139 an invasive cancer up to 31st December 2011. ER and PR were identified by immunohistochemistry (IHC) and HER2 by silver-enhanced in situ hybridisation (SISH) as well as IHC. RESULTS: ER (n=112), PR (n=113) and HER2 (n=114) status from both the primary DCIS and the corresponding relapse were assessed and were demonstrated to be discordant in 15.1%, 29.2% and 10.5% respectively. The receptor conversion was both from negative to positive and from positive to negative with no general pattern being seen in spite of sub-dividing into in situ relapse and invasive relapse. However, primary DCIS was HER2 positive in 40.3% whereas in situ and invasive relapses were HER2 positive in 42.9% and 34.5% respectively. CONCLUSIONS: Receptor conversion for ER, PR and HER2 status occurred between primary DCIS and corresponding local relapse in 10-30%. This study could not confirm that HER2 overexpression in primary DCIS had any impact on tumour progression to invasive cancer which has been proposed.
Authors: Carina Strell; Janna Paulsson; Shao-Bo Jin; Nicholas P Tobin; Artur Mezheyeuski; Pernilla Roswall; Ceren Mutgan; Nicholas Mitsios; Hemming Johansson; Sarah Marie Wickberg; Jessica Svedlund; Mats Nilsson; Per Hall; Jan Mulder; Derek C Radisky; Kristian Pietras; Jonas Bergh; Urban Lendahl; Fredrik Wärnberg; Arne Östman Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506
Authors: Irina Velikyan; Anders Wennborg; Joachim Feldwisch; Henrik Lindman; Jörgen Carlsson; Jens Sörensen Journal: Am J Nucl Med Mol Imaging Date: 2016-04-24
Authors: Jens Sörensen; Irina Velikyan; Dan Sandberg; Anders Wennborg; Joachim Feldwisch; Vladimir Tolmachev; Anna Orlova; Mattias Sandström; Mark Lubberink; Helena Olofsson; Jörgen Carlsson; Henrik Lindman Journal: Theranostics Date: 2016-01-01 Impact factor: 11.556
Authors: Govindasamy-Muralidharan Karthik; Mattias Rantalainen; Gustav Stålhammar; John Lövrot; Ikram Ullah; Amjad Alkodsi; Ran Ma; Lena Wedlund; Johan Lindberg; Jan Frisell; Jonas Bergh; Johan Hartman Journal: BMC Cancer Date: 2017-11-29 Impact factor: 4.430
Authors: Dan Sandberg; Vladimir Tolmachev; Irina Velikyan; Helena Olofsson; Anders Wennborg; Joachim Feldwisch; Jörgen Carlsson; Henrik Lindman; Jens Sörensen Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-06 Impact factor: 9.236
Authors: Mieke R Van Bockstal; Marie C Agahozo; Linetta B Koppert; Carolien H M van Deurzen Journal: Int J Cancer Date: 2019-05-08 Impact factor: 7.396